361 Capital’s Puma Biotechnology PBYI Stock Holding History

361 Capital’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-18,552	Closed	-$1.26M	–	368
2018 Q1	$1.26M	Buy	+18,552	New	+$1.39M	0.31%	203

Other funds holding PBYI

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

361 Capital's PBYI Position: Q2 2018 in Review

361 Capital sold out of Puma Biotechnology (PBYI) in Q2 2018, closing a stake of 18,552 shares — an estimated $1.26M sold.

361 Capital first reported a position in PBYI in Q1 2018 and held it in 1 quarter. The position peaked at $1.26M in Q1 2018. 174 funds tracked by Wall St. Rank hold PBYI as of Q2 2018.

361 Capital reported no remaining Puma Biotechnology position as of Q2 2018 after selling out during the quarter.
361 Capital sold 18,552 Puma Biotechnology shares in Q2 2018, an estimated $1.26M.
361 Capital first reported a position in Puma Biotechnology in Q1 2018 and held it in 1 quarter.
361 Capital's Puma Biotechnology position peaked at $1.26M in Q1 2018.
174 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2018.

Based on 361 Capital's 13F filing for Q2 2018, filed 14 Aug 2018.